who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

How McKesson (MCK) makes money: Q1 FY2027 revenue breakdown

US GAAP, Q1 FY27 · quarter ended 06/30/2026 · released Aug 5

This is the previous report. The new report for Q2 FY2027 came out on Nov 4, 2026 — breakdown in progress

Net Income (consolidated)

$1,032M

up 24.2% y/y

Revenues

$105,380M

up 7.7% y/y

Operating Income

$1,319M

up 27.3% y/y

New report

out Nov 4

breakdown in progress

The quarter in brief

The distributor's razor-thin machine ran faster and better — revenue +8%, operating income +27%, adjusted EPS +20% — while the headline 22% drop in net income to shareholders is accounting noise: a one-time $293M redemption-value adjustment for the Medical-Surgical minority stake sold to Apollo ahead of the Wellverse spin-off.

Key growth driver: Oncology & Multispecialty — the fastest-growing revenue line: $14,200, +33% y/y. · by the Q1 FY2027 report

How does McKesson make money?

McKesson brought in $105 billion of revenue in Q1 FY2027, up 7.7% year over year. The largest source was North American Pharmaceutical: ≈$86.8 billion, or 82% of the total, followed by Oncology & Multispecialty (≈$14.2B, 13%) and Medical-Surgical (≈$2.78B, 3%); other lines add the remaining 2%. Net income for the quarter was $1.03 billion, up 24.2% year over year.

Revenue by source, Q1 FY2027
  • North American Pharmaceutical≈$86.8B · 82% · +5%
  • Oncology & Multispecialty≈$14.2B · 13% · +33%
  • Medical-Surgical≈$2.78B · 3% · +4%
  • Prescription Tech≈$1.60B · 2% · +9%

Shares of $105B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.

All figures in $M.

Sankey diagram of MCK (McKesson) earnings report for Q1 FY2027: revenue, costs and profitNorth AmericanPharmaceutical ≈$86,800 · +5%Oncology & Multispecialty ≈$14,200 · +33%Prescription Tech ≈$1,600 · +9%Medical-Surgical ≈$2,780 · +4%Revenues$105,380 · +7.7%Cost of Sales$101,695 · +7.6%Gross Profit$3,685 · +12.4%3.5% marginSelling,Distribution, G&A$2,264 · +3.1%Restructuring &Impairment$136 · vs $47LitigationCredit, net$34 · vs $0Operating Income$1,319 · +27.3%1.25% of revenueOther Income, net$66 · +3.1%Interest Expense$77 · +57%Pre-Tax Income$1,308 · +24.4%Income Tax$276 · ETR 21.1%Net Income(consolidated)$1,032 · +24.2%Noncontrolling Interests(incl. $293M adj.)$418 · vs $47Net Income to Shareholders$614 · -21.7%adjusted EPS +20%
Sankey diagram of MCK (McKesson) earnings report for Q1 FY2027: revenue, costs and profit
Line itemAmount and change
North American Pharmaceutical ≈$86,800 · +5%
Oncology & Multispecialty ≈$14,200 · +33%
Prescription Tech ≈$1,600 · +9%
Medical-Surgical ≈$2,780 · +4%
Revenues$105,380 · +7.7%
Cost of Sales$101,695 · +7.6%
Gross Profit$3,685 · +12.4% · 3.5% margin
Selling, Distribution, G&A$2,264 · +3.1%
Restructuring & Impairment$136 · vs $47
Litigation Credit, net$34 · vs $0
Operating Income$1,319 · +27.3% · 1.25% of revenue
Other Income, net$66 · +3.1%
Interest Expense$77 · +57%
Pre-Tax Income$1,308 · +24.4%
Income Tax$276 · ETR 21.1%
Net Income (consolidated)$1,032 · +24.2%
Noncontrolling Interests (incl. $293M adj.)$418 · vs $47
Net Income to Shareholders$614 · -21.7% · adjusted EPS +20%

Verdict: the distributor's razor-thin machine ran faster and better — revenue +8%, operating income +27%, adjusted EPS +20% — while the headline 22% drop in net income to shareholders is accounting noise: a one-time $293M redemption-value adjustment for the Medical-Surgical minority stake sold to Apollo ahead of the Wellverse spin-off.

Quarter used $220M of operating cash (seasonal working capital; FCF −$372M); returned $2.6B to shareholders ($2.5B buybacks incl. ASR). Dividend raised 15% to $0.94/sh — tenth consecutive annual increase. FY2027 adjusted EPS guidance raised to $44.20-45.00.

Source and notation

* marks non-cash / ≈ estimated. Segment revenues are press-release approximations. Source: McKesson press release 8-K EX-99.1 (SEC EDGAR).

Open as an image: McKesson (MCK), Q1 FY2027 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “McKesson (MCK) Q1 FY2027: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/mck. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/mck"><img src="https://whoreportstoday.com/t/mck/img/mckesson-mck-earnings-sankey.png" alt="McKesson (MCK) Q1 FY2027: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/mck">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/mck/img/mckesson-mck-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/mck">McKesson (MCK) Q1 FY2027 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. · Text: Wikipedia, CC BY-SA 4.0, abridged

The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees. The company is headquartered in Irving, Texas. It is a component of the S&P 500 and is listed on the New York Stock Exchange, where it is traded under the ticker symbol "MCK".

Company guidance

PeriodCompany guidanceA year agoImplied growth
FY2027EPS (non-GAAP) $45.60–46.40 (raised)revenue $403.4BEPS (GAAP) $38.38—

Same quarter a year ago (ended December 31, 2025): revenue $106.2B, EPS (GAAP) $9.59

How we calculate

EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

Guidance comes from the company's earnings release (Form 8-K filed Nov 4, 2026); every figure is checked against the release text.

The company's release on SEC EDGAR (8-K exhibit) ↗

MCK earnings history: past report dates

Nov 4, 2026 Wed4:06 pmafter market closeSep 30, 2026$111B+8% y/y$10.44+17% y/y
Aug 5, 2026 Wed4:06 pmafter market closeJun 30, 2026$105B+8% y/y$5.15−18% y/y
May 7, 2026 Thu4:07 pmafter market closeMar 31, 2026≈$96.3B+6% y/y≈$13.62+38% y/y
Feb 4, 2026 Wed4:05 pmafter market closeDec 31, 2025$106B+11% y/y$9.59+38% y/y
Nov 5, 2025 Wed4:05 pmafter market closeSep 30, 2025$103B+10% y/y$8.92+377% y/y
Aug 6, 2025 Wed4:06 pmafter market closeJun 30, 2025$97.8B+23% y/y$6.25−11% y/y
May 8, 2025 Thu4:06 pmafter market closeMar 31, 2025≈$90.8B+19% y/y≈$9.90+64% y/y
Feb 5, 2025 Wed4:05 pmafter market closeDec 31, 2024$95.3B+18% y/y$6.95+57% y/y
Nov 6, 2024 Wed4:05 pmafter market closeSep 30, 2024$93.7B+21% y/y$1.87−62% y/y
Aug 7, 2024 Wed4:05 pmafter market closeJun 30, 2024$79.3B+6% y/y$7.00−0% y/y
May 7, 2024 Tue4:05 pmafter market closeMar 31, 2024≈$76.4B+11% y/y≈$6.03+5% y/y
Feb 7, 2024 Wed4:05 pmafter market closeDec 31, 2023$80.9B+15% y/y$4.42−42% y/y
Nov 1, 2023 Wed4:05 pmafter market closeSep 30, 2023$77.2B+10% y/y$4.92−23% y/y
Aug 2, 2023 Wed4:05 pmafter market closeJun 30, 2023$74.5B+11% y/y$7.02+33% y/y
May 8, 2023 Mon4:05 pmafter market closeMar 31, 2023≈$68.9B+4% y/y≈$5.73+135% y/y
Show all 15 reports since 2023Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

McKesson: 16-year financials

FY2026403,4306,2124,7625,719381
FY2025359,0514,4223,2955,548345
FY2024308,9513,9093,0023,883314
FY2023276,7114,3813,5604,769292
FY2022263,9662,0381,1144,046277
FY2021238,228−5,040−4,5394,091276
FY2020231,0512,4899004,012294
FY2019214,319886343,610292
FY2018208,357762673,940262
FY2017198,5337,1225,0704,340253
FY2016190,8843,5452,2583,184244
FY2015179,0452,9681,4762,736227
FY2014137,3922,4391,2632,858214
FY2013122,1962,3471,3382,242194
FY2012122,3212,1241,4032,729195
FY2011112,0841,8211,2022,105171

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The company’s fiscal year doesn’t match the calendar year, so years follow the company’s own labels. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.

McKesson: 15-year balance sheet

YearAssetsEquityDebtCashCurrent assetsCurrent liabilities
202682,323−2,1726,5263,97557,21067,017
202575,140−2,0745,6545,69155,39861,604
202467,443−1,9715,6294,58347,97052,357
202362,320−1,8575,5944,67844,29247,957
202263,298−2,2725,8793,53246,23148,466
202165,015−217,1486,27845,38244,103
202061,2475,0927,3874,01542,22242,624
201959,6728,0947,5952,98138,46537,626
201860,3819,8047,8802,67237,13636,685
201760,96911,0958,5452,78336,94835,612
201656,5238,9248,1144,04838,43535,069
201553,8708,0019,8445,34136,67033,497
201451,7598,52210,5944,19332,83629,615
201334,7867,0704,8732,45623,17021,357
201233,0936,8313,5803,14923,60321,686

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow

6 months ended 2026-09-30 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated2,8501,502+1,348
· incl. D&A (non-cash add-back)depreciation & amortization139124
Capexpurchases of property & equipment−177−217+40
Free cash flow ≈operating cash flow − capex2,6731,285+1,388
Investing activities, netcapex, acquisitions, securities−344−3,588+3,244
· incl. acquisitionsbusinesses net of cash acquired−23−3,389+3,366
Financing activities, netdebt, buybacks, dividends58215−157
· incl. buybacksrepurchases of common stock−3,424−1,399−2,025
· incl. dividends paid−198−179−19
FX effect on cash−1324−37
Net change in cash2,551−1,847+4,398
How to read the table

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Shareholders’ equity at Sep 30, 2026: −$4.0B (−4.3% of total assets). Other S&P 500 companies with negative equity →

Corporate governance

1.5/2mostly good

  • May 2023McKesson settled the Evanston Police Pension Fund shareholder class action (earnings inflated in 2013–2017 by a generic-drug price-fixing conspiracy) for $141M, paid by insurers in February 2023. sec.gov ↗
  • May 2026FY2026 10-K: a single class of common stock; diluted share count −22.7% over 5 years, dividend up from $1.67 to $3.17. sec.gov ↗
1 more fact and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Jun 20262026 proxy: there were no reportable related-party transactions in FY2026. sec.gov ↗

Scoring: 2.0 −0.5 (criterion 9: Evanston shareholder class action over concealed generic-drug price fixing settled for $141M, 2022–2023) = 1.5

Share classes
Single class — MCK common stock on the NYSE (cover of FY2026 10-K); everything else is notes.
Dilution
Diluted share count FY2021→FY2026 −22.7% (XBRL); SBC 0.1% of revenue.
Disclosure
Full 10-K/10-Q reporting.
Dividends
Dividend raised every year: $1.67 (FY2021) → $3.17 (FY2026); buybacks of $3–4.8B a year.
Lawsuits & regulators
Evanston Police Pension Fund suit (10(b), 2018) settled for $141M (insurance-funded, no admission) → −0.5; the HBOC suits (settled 2005–2006) are older than 15 years and not counted; opioid settlements are not shareholder suits — no deduction.
Related parties
2026 proxy: "there were no reportable related-party transactions in FY2026."

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies with revenue growth 10 years in a row · S&P 500 companies that paid dividends 10 years without a gap · S&P 500 companies shrinking their share count

McKesson (MCK) earnings: FAQ

How does McKesson make money?

McKesson brought in $105 billion of revenue in Q1 FY2027, up 7.7% year over year. The largest source was North American Pharmaceutical: ≈$86.8 billion, or 82% of the total, followed by Oncology & Multispecialty (≈$14.2B, 13%) and Medical-Surgical (≈$2.78B, 3%); other lines add the remaining 2%. Net income for the quarter was $1.03 billion, up 24.2% year over year.

When is MCK's next earnings date?

We have not yet seen an announcement of the date from McKesson (MCK). Based on last year's report on Feb 4, 2026, the next report is expected around Feb 3, 2027.

What time does MCK report earnings?

McKesson usually reports after market close: its latest results release was filed with the SEC at 4:06 pm ET on Nov 4, 2026.

When did MCK last report earnings?

McKesson reported Q1 FY2027 results on Aug 5, 2026.

What has McKesson guided for FY2027?

Company guidance for FY2027: EPS (non-GAAP) $45.60–46.40 (raised). A year ago (FY2026): revenue $403.4B, EPS (GAAP) $38.38. Source: the company's earnings release (Form 8-K filed Nov 4, 2026).

Where can I find McKesson's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to MCK's filings; this page breaks the latest report down in a Sankey chart.

What was MCK's net income in Q1 FY2027?

McKesson reported net income of $1,032M for Q1 FY2027 (+24.2% year over year), under US GAAP.

Does McKesson pay dividends?

Yes. In fiscal 2026, McKesson paid $381M in dividends on its common stock, per its 10-K. Earlier years are in the 16-year table above.

How has McKesson's revenue changed since 2011?

Per its 10-K filings, revenue grew 3.6x: $112,084M in fiscal 2011 and $403,430M in fiscal 2026. The latest year is the highest in the table. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: MDT · Q1 2027 · MRK · Q3 2026 · MRNA · Q2 2026 · MTD · Q3 2026 · PFE · Q3 2026 · PODD · Q3 2026 · REGN · Q3 2026 · RMD · Q1 FY2027 · RVTY · Q3 2026 · SOLV · Q2 2026 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy